This study reveals a novel mechanism driving immune evasion in gastric cancer, proposes FAP+CAFs as a potential biomarker for predicting anti-PD-1 therapy resistance, and suggests that targeting the IL-31/STAT6 axis could offer new therapeutic strategies to enhance immunotherapy efficacy. The gene discussed is STAT6; the disease is gastric cancer.